Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
OwnerMichael HUDECEK, Hardikkumar JETANIinventors
Life of this patent
Estimating the term…
Abstract
The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.
Claims105
A composition for use in a method for the treatment of cancer in a patient, the composition comprising:
- (a) A kinase inhibitor;
- and
- (b) An FLT3-targeting agent;
- wherein in the method, the composition is to be administered to the patient.
A chimeric antigen receptor capable of binding FLT3.
An FLT3-targeting agent for use in a method of treating cancer.
A kit comprising an FLT3-targeting agent and a kinase inhibitor.
A composition comprising:
- (a) A kinase inhibitor;
- and
- (b) An FLT3-targeting agent.
A combination of FLT3 CAR-T cells and a kinase inhibitor, for use in a method for the treatment of cancer, wherein the combination is to be administered prior to or after an allogeneic hematopoietic stem cell transplantation to treat the cancer.
Dependencies are inferred from the claim text.